The main risk is economic proof, not scientific imagination.
QCi has real assets, cash, and a credible
photonics angle, but it still must show that early orders convert into repeat volume, fab utilization improves enough to fix
gross margins, acquisitions integrate cleanly, and governance catches up. If first
NeuraWave deployments slip or remain one-off, the valuation has little protection.